WHO ICTRP trial
Combined anti-Vascular Endothelial Growth Factor (VEGF) and low-dose…
IRCT20201120049450N6 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT20201120049450N6 |
|---|---|
| Public title | Combined anti-Vascular Endothelial Growth Factor (VEGF) and low-dose triamcinolone intravitreal injections versus anti-VEGF alone for treatment of diabetic macular edema |
| Scientific title | Combined anti-Vascular Endothelial Growth Factor (VEGF) and low-dose triamcinolone intravitreal injections versus anti-VEGF alone for treatment of diabetic macular edema: A Randomized clinical trial |
| Primary sponsor | Shiraz University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 2-3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | retinal disorder. H35;other reti |
| Interventions | Intervention 1: Control group: intravitreal injection of bevacizumab. Intervention 2: Intervention group: intravitreal injection of bevacizumab and triamcinolone. |
| Registration date | Apr 20, 2025 |
| Target size | 64 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: